uWink Inc. (UWKI)

[mrmessiah]

In DNDN Case, The 2 trials executed where small and the primary endpoint which was Time To Progression was not meet. The panel was swayed by the Overall Survival, which was also questioned as patients who failed therapy of the DNDN drug where then put on another drug, which could have been the reason the patients lived longer.

The length of survival for the some of the patients was impressive and I for one, even though I didn't own the stock, was happy they recommended it for approval.

If the approval had not been so much in question I don't think we would have seen this type of rise in share price. A lot of short interest was fuel for the fire. It would not surprise me to see the price once again slip below $10 before it comes up for FDA approval.